FORM 4	4
--------	---

Check this box if no
longer subject to
Section 16. Form 4 or
Form 5 obligations
may continue. See
Instruction 1(b).

(Print or Type Responses)

#### UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response... 0.5

#### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Per FROM STEPHEN					5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner Officer (give title below) Other (specify below) Executive Chairman						
(Last) (First) C/O EYEGATE PHARMACEU INC., 271 WAVERLEY OAKS SUITE 108	,	FICALS, $11/02/2021$									
(Street) WALTHAM, MA 02452	4. If Amendment, Date Original Filed(Month/Day/Year)						6. Individual or Joint/Group Filing(Check Applicable Line) _X_Form filed by One Reporting PersonForm filed by More than One Reporting Person				
(City) (State)	(Zip)	Table I - Non-Derivative Securities Acq					s Acqu	ired, Disposed of, or Beneficially Owned			
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	Execution Date, if		tion	(A) or Disposed of (D)			5. Amount of Securities 6. 7. Na Beneficially Owned Following Reported Transaction(s) Form: Bene (Instr. 3 and 4) Direct (D) Own-			
		(Wohlly Day) Fear)	Code	v	Amount	(A) or (D)	Price	(1150. 5 and 4)	or Indirect (I) (Instr. 4)	*	
Common Stock	11/02/2021		F <mark>(1)</mark>		250	D	\$ 1.98	68,292	D		

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless

SEC 1474 (9-02)

the form displays a currently valid OMB control number.

### Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

			(e.g.,	outs, cans, w	arrar	ns, op	tions, conver	uble securi	illes)					
1. Title of	2.		3A. Deemed	4.	5.		6. Date Exer	cisable	7. Tit	le and	8. Price of	9. Number of	10.	11. Nature
Derivative	Conversion	Date	Execution Date, if	Transaction	Num	ıber	and Expirati	on Date	Amo	unt of	Derivative	Derivative	Ownership	of Indirect
Security	or Exercise	(Month/Day/Year)	any	Code	of		(Month/Day	/Year)	Unde	rlying	Security	Securities	Form of	Beneficial
(Instr. 3)	Price of		(Month/Day/Year)	(Instr. 8)	Deri	vative			Secur	rities	(Instr. 5)	Beneficially	Derivative	Ownership
	Derivative					rities			(Instr	: 3 and		Owned	Security:	(Instr. 4)
	Security				Acqu	uired			4)			Following	Direct (D)	
					(A) (							1	or Indirect	
						osed						Transaction(s)	(I)	
					of (I	/						(Instr. 4)	(Instr. 4)	
					(Inst	· ·								
					4, an	id 5)								
										Amount				
							Dete	E		or				
								Expiration	Title	Number				
							Exercisable	Date		of				
				Code V	(A)	(D)				Shares				

## **Reporting Owners**

	Relationships						
Reporting Owner Name / Address	Director	10% Owner	Officer	Other			
FROM STEPHEN C/O EYEGATE PHARMACEUTICALS, INC. 271 WAVERLEY OAKS ROAD, SUITE 108 WALTHAM, MA 02452	Х		Executive Chairman				

## **Signatures**

/s/ Sarah Romano, Attorney-in-Fact*	11/03/2021
**Signature of Reporting Person	Date

# **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Sale of shares to cover taxes due on restricted stock that vested on 11/01/2021.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.